This field guide is designed for use by FHI 360 staff and partner organizations responsible for ensuring quality clinical services, at both facility and non-facility levels. The guide provides general information on how to organize, implement and follow up on quality assurance/quality improvement cl...inical facility and service assessments.
The accompanying checklists are intended to be used with the clinical facility assessment guide.
more
Reach the Unreached - FIND, TREAT, CURE TB, SAVE LIVES
WHO/HTM/HIV/2007.01 WHO/HTM/TB/2007.380
Towards gender - transformative HIV and TB responses
На пути к гендерно-преобразовательным мерам против ВИЧ и ТБ
Advance Copy
Accessed: 08.03.2020
A Training Curriculum for Multidisciplinary Healthcare Teams. This innovative training package aims to empower multidisciplinary health workers to have the confidence and skills to provide comprehensive, youth-friendly HIV services that support adolescents’ healthy development, psychosocial well b...eing, retention, adherence, sexual and reproductive health, and eventual transition to adult HIV services.
more
For the first time in almost 50 years there are two new drugs for the treatment of drug-resistant TB (DR-TB): bedaquiline and delamanid. There has also been increased attention given to the safety and efficacy of “re-purposed” drugs that have been widely used to treat other infections but are al...so showing promise in the treatment of DR-TB, including linezolid and clofazimine. This special supplemental guide has been developed for nurses, because it is essential that nurses be provided with material that maximizes their ability to provide optimal support to patients who are receiving new and re-purposed drugs
more
HIV & AIDS Treatment in Practice No.199
Progress in diagnosis: Akey in overcoming the MDR-TB crisis.
The expanse-TV project progress and impact brief.
KNCV Tuberculosis Foundation - Your partner in the fight against TB
Accessed November 2017
Revised National TB Control Programme. Annual Status Report
ПАКЕТ МЕР ПО РЕАЛИЗАЦИИ ПОЛИТИКИ В ОТНОШЕНИИ ВНЕДРЕНИЯ НОВЫХ ПРОТИВОТУБЕРКУЛЕЗНЫХ ПРЕПАРАТОВ